About OticPharma
OticPharma is a company based in Yehud (Israel) founded in 2008. OticPharma has raised $4.3 million across 1 funding round from investors including Orbimed. OticPharma has completed 1 acquisition, including Tokai Pharmaceuticals. OticPharma operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Yehud, Israel
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$4.3 M (USD)
in 1 rounds
-
Latest Funding Round
$4.3 M (USD), Series A
Feb 26, 2012
- Investors
-
Employee Count
Not available
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of OticPharma
OticPharma has successfully raised a total of $4.3M through 1 strategic funding round. The most recent funding activity was a Series A round of $4.3 million completed in February 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in OticPharma
OticPharma has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Orbimed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked |
Investor details for OticPharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by OticPharma
OticPharma has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Tokai Pharmaceuticals.
Investment portfolio details for OticPharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Therapies for prostate cancer and hormonally-driven diseases are developed.
|
Locked | Locked | 2004 | Locked |
Complete acquisition details for OticPharma
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - OticPharma
Detailed financials for OticPharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Oticpharma Comparisons
Peer comparison for OticPharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of OticPharma
OticPharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
CRISPR-engineered cell and gene therapies are developed for research applications.
|
Detailed competitors of OticPharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Oticpharma
Complete news archive for OticPharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about OticPharma
OticPharma was founded in 2008 and raised its 1st funding round 4 years after it was founded.
OticPharma is headquartered in Yehud, Israel. It is registered at Yehud, Central District, Israel.
OticPharma is a funded company, having raised a total of $4.3M across 1 funding round to date.
OticPharma is a clinical-stage company active in the field of ear, nose, and throat disorders. Its current product candidates are based on FoamOtic, a proprietary foam-based drug delivery system that provides sustained exposure of drugs. Its lead product, FoamOtic Externa, is an investigational proprietary, foam-based, extended-release formulation of ciprofloxacin antibiotic, which has been designated for self-administration to potentially treat acute otitis externa in minor and adult patients. It has completed a successful Phase 2 clinical trial with FoamOtic Externa in minor and adult patients with acute otitis externa and is currently planning the Phase 3 program. In November 2015, it acquired Novel Otitis Media Program from Otodyne.
OticPharma's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
OticPharma has made 1 acquisition, including Tokai Pharmaceuticals.
OticPharma has 1 investor. Key investors include Orbimed.